Skip to main content
SpringerLink
Log in

Metabolomics for the Individualized Therapy of Androgen Deficiency Syndrome in Male Adults

  • Chapter
  • First Online:
Genetics Meets Metabolomics

  • 1724 Accesses

Abstract

Testosterone is the major circulating androgen in men with a physiological age-related decline in the aging male. Late-onset hypogonadism or Androgen Deficiency Syndrome (ADS) is a “syndromic” diagnosis including both, persistent low testosterone concentrations together with clinical symptoms including erectile dysfunction, low libido, decreased muscle mass and strength, increased body fat, decreased vitality, and depressed mood. But due to its unspecific symptoms, treatment goals, and monitoring parameters, there are many uncertainties concerning the diagnosis, therapy, and monitoring of ADS to date. The present work intends to introduce the application of metabolomics as a novel and promising tool for the improved diagnosis, therapy, and monitoring of ADS. We will outline the current uncertainties and limitations in the diagnosis and therapy of ADS to subsequently explore the scientific opportunities of metabolomics to account for the specific metabolic requirements and characteristics of the individual patient, better understand the metabolic deviations in testosterone deficiency, and monitor the biochemical changes induced by testosterone replacement therapy. We also discuss the potential of metabolomics to optimize the effectiveness and safety of individualized testosterone replacement therapy, and to thereby significantly reduce the side effects and associated health care costs of ADS treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mooradian AD, Morley JE, Korenman SG (1987) Biological actions of androgens. Endocr Rev 8:1–28

    Article  PubMed  CAS  Google Scholar 

  2. Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833–876

    Article  PubMed  CAS  Google Scholar 

  3. Rommerts FFG (2004) Testosterone: an overview of biosynthesis, transport, metabolism and non-genomic actions. In: Nieschlag E, Behre H (eds) Testosterone: action, deficiency, substitution. Cambridge University Press, Cambridge

    Google Scholar 

  4. Sandberg AA, Slaunwhite WR Jr (1956) Metabolism of 4-C14-testosterone in human subjects I. Distribution in bile, blood, feces and urine. J Clin Invest 35:1331–1339

    Article  PubMed  CAS  Google Scholar 

  5. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87:589–598

    Article  PubMed  CAS  Google Scholar 

  6. Haring R, Ittermann T, Volzke H, Krebs A, Zygmunt M, Felix SB, Grabe HJ, Nauck M, Wallaschofski H (2010) Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania. Aging Male 13:247–257

    Article  PubMed  CAS  Google Scholar 

  7. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of Aging. J Clin Endocrinol Metab 86:724–731

    Article  PubMed  CAS  Google Scholar 

  8. Morley JE, Kaiser FE, Perry HM 3, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ (1997) Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46:410–413

    Article  PubMed  CAS  Google Scholar 

  9. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH (1997) Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol 146:609–617

    Article  PubMed  CAS  Google Scholar 

  10. Vermeulen A, Kaufman JM, Giagulli VA (1996) Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 81:1821–1826

    Article  PubMed  CAS  Google Scholar 

  11. Khaw KT, Barrett-Connor E (1992) Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 2:675–682

    Article  PubMed  CAS  Google Scholar 

  12. Haring R, Baumeister SE, Völzke H, Dorr M, Felix SB, Kroemer HK, Nauck M, Wallaschofski H (2011) Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehabil 18:86–96

    PubMed  Google Scholar 

  13. Torkler S, Wallaschofski H, Baumeister SE, Völzke H, Dörr M, Felix SB, Rettig R, Nauck MA, Haring R (2010) Inverse association between total testosterone concentrations, incident hypertension, and blood pressure. Aging Male 14:176–182

    Article  PubMed  Google Scholar 

  14. Haring R, Volzke H, Felix SB, Schipf S, Dorr M, Rosskopf D, Nauck M, Schofl C, Wallaschofski H (2009) Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 58:2027–2031

    Article  PubMed  CAS  Google Scholar 

  15. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB (2006) Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91:843–850

    Article  PubMed  CAS  Google Scholar 

  16. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT (2004) Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036–1041

    Article  PubMed  CAS  Google Scholar 

  17. Schipf S, Haring R, Friedrich N, Nauck MA, Lau K, Alte D, Stang A, Völzke H, Wallaschofski H (2011) Low total testosterone is associated with increased risk of incident type 2 diabetes mellitus in men: results from the study of health in Pomerania (SHIP). Aging Male 14:168–175

    Article  PubMed  CAS  Google Scholar 

  18. Vikan T, Schirmer H, Njolstad I, Svartberg J (2010) Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol 162:747–754

    Article  PubMed  CAS  Google Scholar 

  19. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT & Wittert GA (2011) Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 96:3007–3019

    Article  PubMed  CAS  Google Scholar 

  20. Haring R, Volzke H, Steveling A, Krebs A, Felix SB, Schofl C, Dorr M, Nauck M, Wallaschofski H (2010) Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur Heart J 31:1494–1501

    Article  PubMed  CAS  Google Scholar 

  21. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 116:2694–2701

    Article  PubMed  CAS  Google Scholar 

  22. Laughlin GA, Barrett-Connor E, Bergstrom J (2008) Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93:68–75

    Article  PubMed  CAS  Google Scholar 

  23. Barrett-Connor E, Khaw KT, Yen SS (1990) Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol 132:895–901

    PubMed  CAS  Google Scholar 

  24. Swartz CM, Young MA (1987) Low serum testosterone and myocardial infarction in geriatric male inpatients. J Am Geriatr Soc 35:39–44

    PubMed  CAS  Google Scholar 

  25. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R, Rauramaa R, Salonen JT (2003) Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 149:601–608

    Article  PubMed  CAS  Google Scholar 

  26. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. J Clin Endocrinol Metab 93:2737–2745

    Article  PubMed  CAS  Google Scholar 

  27. Wang TJ (2008) New cardiovascular risk factors exist, but are they clinically useful? Eur Heart J 29:441–444

    Article  PubMed  CAS  Google Scholar 

  28. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM (2011) Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 97:870–875

    Article  PubMed  CAS  Google Scholar 

  29. McLachlan RI (2010) Certainly more guidelines than rules. J Clin Endocrinol Metab 95:2610–2613

    Article  PubMed  CAS  Google Scholar 

  30. Maggio M, Basaria S (2009) Welcoming low testosterone as a cardiovascular risk factor. Int J Impot Res 21:261–264

    Article  PubMed  CAS  Google Scholar 

  31. Nieschlag E, Behre H (2004) Clinical uses of testosterone in hypogonadism and other conditions. In: Nieschlag E, Behre H (eds) Testosterone: action, deficiency, substitution. Cambridge University Press, Cambridge

    Google Scholar 

  32. Isidori AM, Lenzi A (2007) Testosterone replacement therapy: what we know is not yet enough. Mayo Clin Proc 82:11–13

    PubMed  Google Scholar 

  33. Snyder PJ (2008) Decreasing testosterone with increasing age: more factors, more questions. J Clin Endocrinol Metab 93:2477–2478

    Article  PubMed  CAS  Google Scholar 

  34. Travison TG, Araujo AB, Kupelian V, O’Donnell AB, McKinlay JB (2007) The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 92:549–555

    Article  PubMed  CAS  Google Scholar 

  35. Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB (2004) Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab 89:5920–5926

    Article  PubMed  CAS  Google Scholar 

  36. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM (2010) Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 95:2536–2559

    Article  PubMed  CAS  Google Scholar 

  37. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC (2009) Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 30:1–9

    Article  PubMed  Google Scholar 

  38. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS (2004) Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 89:534–543

    Article  PubMed  CAS  Google Scholar 

  39. Dorgan JF, Fears TR, McMahon RP, Aronson Friedman L, Patterson BH, Greenhut SF (2002) Measurement of steroid sex hormones in serum: a comparison of radioimmunoassay and mass spectrometry. Steroids 67:151–158

    Article  PubMed  CAS  Google Scholar 

  40. Hsing AW, Stanczyk FZ, Belanger A, Schroeder P, Chang L, Falk RT, Fears TR (2007) Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol Biomarkers Prev 16:1004–1008

    Article  PubMed  CAS  Google Scholar 

  41. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P (2003) Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 49:1381–1395

    Article  PubMed  CAS  Google Scholar 

  42. Vesper HW, Bhasin S, Wang C, Tai SS, Dodge LA, Singh RJ, Nelson J, Ohorodnik S, Clarke NJ, Salameh WA, Parker CR Jr, Razdan R, Monsell EA, Myers GL (2009) Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods. Steroids 74:498–503

    Article  PubMed  CAS  Google Scholar 

  43. Stanczyk FZ, Clarke NJ (2010) Advantages and challenges of mass spectrometry assays for steroid hormones. J Steroid Biochem Mol Biol 121:491–495

    Article  PubMed  CAS  Google Scholar 

  44. Thienpont LM, Van Uytfanghe K, Blincko S, Ramsay CS, Xie H, Doss RC, Keevil BG, Owen LJ, Rockwood AL, Kushnir MM, Chun KY, Chandler DW, Field HP, Sluss PM (2008) State-of-the-art of serum testosterone measurement by isotope dilution-liquid chromatography-­tandem mass spectrometry. Clin Chem 54:1290–1297

    Article  PubMed  CAS  Google Scholar 

  45. Haring R, Spielhagen C, Nauck M (2011) Challenges in the measurement of serum testosterone concentrations as a biomarker of mens health. J Lab Med 35:1–5

    Google Scholar 

  46. Wheeler MJ, Barnes SC (2008) Measurement of testosterone in the diagnosis of hypogonadism in the ageing male. Clin Endocrinol (Oxf) 69:515–525

    Article  CAS  Google Scholar 

  47. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363:123–135

    Article  PubMed  CAS  Google Scholar 

  48. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A (2005) Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 63:381–394

    Article  CAS  Google Scholar 

  49. Wespes E (2010) Current approaches to erectile dysfunction and testosterone deficiency. Minerva Urol Nefrol 62:431–435

    PubMed  CAS  Google Scholar 

  50. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM (2010) Clinical review I: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95:2560–2575

    Article  PubMed  CAS  Google Scholar 

  51. O’Connell MD, Roberts SA, Srinivas-Shankar U, Tajar A, Connolly MJ, Adams JE, Oldham JA, Wu FC (2011) Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men? J Clin Endocrinol Metab 96:454–458

    Article  PubMed  Google Scholar 

  52. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010) Adverse events associated with testosterone administration. New Engl J Med 363:109–122

    Article  PubMed  CAS  Google Scholar 

  53. Vesper HW, Botelho JC (2010) Standardization of testosterone measurements in humans. J Steroid Biochem Mol Biol 121:513–519

    Article  PubMed  CAS  Google Scholar 

  54. Shulaev V (2006) Metabolomics technology and bioinformatics. Br Bioinformatics 7:128–139

    Article  CAS  Google Scholar 

  55. Lindon JC, Nicholson JK (2008) Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Anal Chem 1:45–69

    Article  CAS  Google Scholar 

  56. Lindon JC, Holmes E (2007) A survey of metabonomics approaches for disease characterisation. The handbook of metabonomics and metabolomics. Elsevier, London

    Google Scholar 

  57. Holmes E, Wilson ID, Nicholson JK (2008) Metabolic phenotyping in health and disease. Cell 134:714–717

    Article  PubMed  CAS  Google Scholar 

  58. Lewis GD, Asnani A, Gerszten RE (2008) Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol 52:117–123

    Article  PubMed  CAS  Google Scholar 

  59. Nicholson JK, Lindon JC (2008) Systems biology: metabonomics. Nature 455:1054–1056

    Article  PubMed  CAS  Google Scholar 

  60. Barderas MG, Laborde CM, Posada M, de la Cuesta F, Zubiri I, Vivanco F, Alvarez-Llamas G (2011) Metabolomic profiling for identification of novel potential biomarkers in cardiovascular diseases. J Biomed Biotechnol 2011:1–9

    Article  Google Scholar 

  61. Holmes E, Loo RL, Stamler J, Bictash M, Yap IK, Chan Q, Ebbels T, De Iorio M, Brown IJ, Veselkov KA, Daviglus ML, Kesteloot H, Ueshima H, Zhao L, Nicholson JK, Elliott P (2008) Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453:396–400

    Article  PubMed  CAS  Google Scholar 

  62. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O’Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE (2011) Metabolite profiles and the risk of developing diabetes. Nature Med 17:448–453

    Article  PubMed  Google Scholar 

  63. Mayr M, Yusuf S, Weir G, Chung YL, Mayr U, Yin X, Ladroue C, Madhu B, Roberts N, De Souza A, Fredericks S, Stubbs M, Griffiths JR, Jahangiri M, Xu Q, Camm AJ (2008) Combined metabolomic and proteomic analysis of human a trial fibrillation. J Am Coll Cardiol 51:585–594

    Article  PubMed  CAS  Google Scholar 

  64. Makinen VP, Soininen P, Forsblom C, Parkkonen M, Ingman P, Kaski K, Groop PH, ­Ala-Korpela M (2008) 1 H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol 4:167

    Article  PubMed  Google Scholar 

  65. Nicholson JK (2006) Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol 2:52

    Article  PubMed  Google Scholar 

  66. Gould DC, Petty R, Jacobs HS (2000) For and against: the male menopause–does it exist? BMJ 320:858–861

    Article  PubMed  CAS  Google Scholar 

  67. Morley JE, Perry HM 3rd (2003) Androgen treatment of male hypogonadism in older males. J Steroid Biochem Mol Biol 85:367–373

    Article  PubMed  CAS  Google Scholar 

  68. Perheentupa A, Huhtaniemi I (2007) Does the andropause exist? Nature Clin Pract 3:670–671

    Article  CAS  Google Scholar 

  69. Seidman SN (2006) Normative hypogonadism and depression: does ‘andropause’ exist? Int J Impot Res 18:415–422

    Article  PubMed  CAS  Google Scholar 

  70. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, Clarke S, Schofield PM, McKilligin E, Mosedale DE, Grainger DJ (2002) Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1 H-NMR-based metabonomics. Nat Med 8:1439–1444

    Article  PubMed  CAS  Google Scholar 

  71. Moolenaar SH, Engelke UF, Wevers RA (2003) Proton nuclear magnetic resonance spectroscopy of body fluids in the field of inborn errors of metabolism. Ann Clin Biochem 40:16–24

    Article  PubMed  CAS  Google Scholar 

  72. Robosky LC, Wells DF, Egnash LA, Manning ML, Reily MD, Robertson DG (2005) Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. Toxicol Sci 87:277–284

    Article  PubMed  CAS  Google Scholar 

  73. Wopereis S, Rubingh CM, van Erk MJ, Verheij ER, van Vliet T, Cnubben NH, Smilde AK, van der Greef J, van Ommen B, Hendriks HF (2009) Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes. PLoS One 4:e4525

    Article  PubMed  Google Scholar 

  74. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P (2006) Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 114:1829–1837

    Article  PubMed  CAS  Google Scholar 

  75. Schatzl G, Madersbacher S, Temml C, Krenn-Schinkel K, Nader A, Sregi G, Lapin A, Hermann M, Berger P, Marberger M (2003) Serum androgen levels in men: impact of health status and age. Urology 61:629–633

    Article  PubMed  Google Scholar 

  76. Mareck U, Geyer H, Opfermann G, Thevis M, Schanzer W (2008) Factors influencing the steroid profile in doping control analysis. J Mass Spectrom 43:877–891

    Article  PubMed  CAS  Google Scholar 

  77. Badoud F, Grata E, Boccard J, Guillarme D, Veuthey JL, Rudaz S, Saugy M (2011) Quantification of glucuronidated and sulfated steroids in human urine by ultra-high pressure liquid chromatography quadrupole time-of-flight mass spectrometry. Anal Bioanal Chem 400:503–516

    Article  PubMed  CAS  Google Scholar 

  78. Bean KA, Henion JD (1997) Direct determination of anabolic steroid conjugates in human urine by combined high-performance liquid chromatography and tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 690:65–75

    Article  PubMed  CAS  Google Scholar 

  79. Strahm E, Kohler I, Rudaz S, Martel S, Carrupt PA, Veuthey JL, Saugy M, Saudan C (2008) Isolation and quantification by high-performance liquid chromatography-ion-trap mass spectrometry of androgen sulfoconjugates in human urine. J Chromatogr 1196–1197:153–160

    Google Scholar 

  80. Robertson DG, Reily MD, Cantor GH (2007) Metabonomics in preclinical pharmaceutical discovery and development. In: Lindon JC, Nicholson JK, Holmes E (eds) The handbook of metabonomics and metabolomics. Elsevier, London

    Google Scholar 

  81. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073–1077

    Article  PubMed  CAS  Google Scholar 

  82. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, Berriz GF, Roth FP, Gerszten RE (2005) Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112:3868–3875

    Article  PubMed  CAS  Google Scholar 

  83. Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, Vasan RS, Carr SA, Thadhani R, Gerszten RE, Mootha VK (2008) Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol 4:214

    Article  PubMed  Google Scholar 

  84. Baumgartner C, Lewis GD, Netzer M, Pfeifer B, Gerszten RE (2010) A new data mining approach for profiling and categorizing kinetic patterns of metabolic biomarkers after myocardial injury. Bioinformatics 26:1745–1751

    Article  PubMed  CAS  Google Scholar 

  85. Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M, Farrell L, Asnani A, Cyrille M, Ramanathan A, Shaham O, Berriz G, Lowry PA, Palacios IF, Tasan M, Roth FP, Min J, Baumgartner C, Keshishian H, Addona T, Mootha VK, Rosenzweig A, Carr SA, Fifer MA, Sabatine MS, Gerszten RE (2008) Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 118:3503–3512

    Article  PubMed  CAS  Google Scholar 

  86. Shah SH, Bain JR, Muehlbauer MJ, Stevens RD, Crosslin DR, Haynes C, Dungan J, Newby LK, Hauser ER, Ginsburg GS, Newgard CB, Kraus WE (2010) Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet 3:207–214

    Article  PubMed  CAS  Google Scholar 

  87. Hayflick L (2007) Entropy explains aging, genetic determinism explains longevity, and undefined terminology explains misunderstanding both. PLoS Genet 3:e220

    Article  PubMed  Google Scholar 

  88. Kirkwood TB (2005) Understanding the odd science of aging. Cell 120:437–447

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Strasse, Greifswald, Mecklenburg-Vorpommern, 17475, Germany

    Robin Haring, Kathrin Budde & Henri Wallaschofski M.D.

Authors
  1. Robin Haring
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathrin Budde
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henri Wallaschofski M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robin Haring .

Editor information

Editors and Affiliations

  1. Qatar Foundation-Education City, Weill Cornell Medical College in Qatar, Education City – Qatar Foundation, Doha, 24144, Qatar

    Karsten Suhre

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Haring, R., Budde, K., Wallaschofski, H. (2012). Metabolomics for the Individualized Therapy of Androgen Deficiency Syndrome in Male Adults. In: Suhre, K. (eds) Genetics Meets Metabolomics. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1689-0_10

Download citation

Publish with us

Policies and ethics

Search

Navigation